DOCSLIB.ORG

Towards Antivirals Against VHF Viruses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Towards Antivirals Against VHF Viruses Design of small molecule inhibitors of RNA virus replication Towards antivirals against VHF viruses Johan Neyts Rega Institute, University of Leuven, Belgium Design of small molecule inhibitors of RNA virus replication Gertrude Elion, 1918 - 1999 O N HN H N N N 2 HO O Design of small molecule inhibitors of RNA virus replication Virus Target Drugs on the market Herpes Polymerase Acyclovir, valacyclovir, penciclovir, famiclovir, brivudin, foscarnet, cidofovir HBV RT/polymerase Lamivudine, adefovir, entecavir, telbuvidine HIV Reverse NRTI: zidovudine, didanosine, zalcitabine, stavudine, transcriptase lamivudine, abacavir, tenofovir NNRTI: nevirapine, delavirdine, efavirenz Protease Saquinavir, ritonavir, indinavir, nelfinafir, amprenavir, lopinavir Fusion- CCR5 T20 - Maraviroc Integrase Raltegravir Influenza M2 Amantadine, rimantadine Neuraminidase Oseltamivir, zanamivir RSV Ribavirin HCV Ribavirin + peg interferon Antivirals from the Rega Institute Herpes HBV HIV And more O CMV retinitis Br HN O N HPMPC HO O HO BVDU-TP inhibits the PMEA-TP is chain PMPA-TP is chain viral polymerase terminator terminator HIV TIBO derivatives T-tropic HIV strains CXCR4 antagonists Brivudin Adefovir dipivoxil Tenofovir disoproxyl fumarate RNA viruses? BVDU Bis(POM)-PMEA Bis(POC)-PMPA-fumarate Antivirals from the Rega Institute Herpes HBV HIV And more CMV retinitis O NH Br 2 HN N N O N HPMPC HO N N O P P P O HO BVDU-TP inhibits the PMEA-TP is a chain PMPA-TP is chain viral polymerase terminator terminator HIV TIBO derivatives T-tropic HIV strains CXCR4 antagonists Brivudin Adefovir dipivoxil Tenofovir disoproxyl fumarate RNA viruses? BVDU Bis(POM)-PMEA Bis(POC)-PMPA-fumarate Antivirals from the Rega Institute Herpes HBV HIV And more O NH CMV retinitis NH 2 2 Br N N HN N O O N N N HPMPC O N O O O HO N N P O O O O P P P O O O HO BVDU-TP inhibits the PMEA-TP is a chain PMPA-TP is a chain viral polymerase terminator terminator HIV TIBO derivatives + emtricitabine efavirenz + T-tropic HIV strains CXCR4 antagonists Brivudin Adefovir dipivoxil Tenofovir disoproxyl fumarate RNA viruses? BVDU Bis(POM)-PMEA Bis(POC)-PMPA-fumarate Design of small molecule inhibitors of RNA virus replication Herpes HBV HIV And more O NH CMV retinitis NH 2 2 Br N N HN N O O N N N HPMPC O N O O O HO N N P O O O O P P P O O O HO BVDU-TP inhibits the PMEA-TP is a chain PMPA-TP is a chain viral polymerase terminator terminator HIV TIBO derivatives + emtricitabine efavirenz + T-tropic HIV strains CXCR4 antagonists Brivudin Adefovir dipivoxil Tenofovir disoproxyl fumarate RNA viruses? BVDU Bis(POM)-PMEA Bis(POC)-PMPA-fumarate Design of small molecule inhibitors of RNA virus replication Ribavirin and VHF Active Not (or limited) active Arenaviruses Filoviruses Bunyaviruses Flaviviruses Treatment of suspected or Post exposure prophylaxis [7 confirmed clinical cases of VHF days] [10 days] Intravenous : initial dose of 2g followed by 1 g every 6 hr for 4 days followed by 0.5 g every 8 hr for 6 days Intravenous : Initial dose of 30 mg/kg followed by 15 mg/kg every 6 hr for 4 days, followed by 7.5 mg/kg every 8 hr. Per os : 2 g as loading dose Per os : 2 g / day in 4 doses followed by 4 g/day in 4 doses for 4 days followed by 2 g/day for 6 days Bossi et al., Eurosurveillance (2004) Task Force on Biological & Chemical Agent Threats, European Commission Design of small molecule inhibitors of RNA virus replication Can we design more potent ribavirin analogues? O N H2N N Mechanism of action of ribavirin? N HO O Mycophenolic acid HO OH 1. Inhibition of IMP-dehydrogenase GTP Ribavirin Ribavirin Design of small molecule inhibitors of RNA virus replication 2. Inhibition of the viral polymerase by ribavirin-TP (reovirus, VSV, influenza… ) 3. Inhibition of guanylyltransferase activity and thus capping (sindbis) 4. Induction of an error catastrophe (polio… .) 5. Immunomodulation Crotty et al. (2001) Proc. Natl. Acad. Sci. USA 98, 6895-6900 Design of small molecule inhibitors of RNA virus replication MORE POTENT ANALOGUES OF RIBAVIRIN... O EICAR N EC µg/ml H2N 50 Ribavirin EICAR HC C N YFV-17D 27 1 DENV 25 2 HO O Junin 12 0.2 5- ethynyl 1 beta-D ribofuranosyl imidazole RSV 4 0.2 carboxamide HO OH Measles 8 0.5 but ....EICAR is at least 10-fold more cytostatic in cell culture than ribavirin De Clercq et al., Antimicrob. Agents & Chemother. 35:679-84 Leyssen et al., J. Virol. 80:149-60. Design of small molecule inhibitors of RNA virus replication GTP depletion Anti-YFV activity 125 125 100 100 75 75 % G T50 P 50 % YFV 17D RNA 25 25 0 0 100 25 10 2.5 1 0.25 0.1 0.025 0.01 100 25 10 2.5 1 0.25 0.1 0.025 0.01 [ ] compound (µg/m l) [ ] compound (µg/m l) O O Ribavirin EICAR MPA N N H2N H2N CH3 N N N H3CO HC C O HO HOOC HO O O O CH3 OH HO OH HO OH Design of small molecule inhibitors of RNA virus replication Antiviral activity of ribavirin correlates with GTP depletion MPA EICAR Ribavirin 100 R2 = 0.998 DENV: R² = 0.991 MODV: R² = 0.999 MMLV: R² = 0.987 10 1 0.1 0.01 EC50 for GTP depletion (µg/ml) 0.001 0.001 0.01 0.1 1 10 100 EC50 for inhibition of YFV 17D RNA re plication (µg/ml) Leyssen et al., J. Virol. 80:149-60 Design of small molecule inhibitors of RNA virus replication Correlation between reduction of viral RNA and infectious virus for YFV 1.0E+09 1.0E+09 1.0E+08 Ribavirin 1.0E+08 1.0E+07 1.0E+07 1.0E+06 1.0E+06 1.0E+05 1.0E+05 1.0E+04 1.0E+04 1.0E+03 1.0E+03 1.0E+02 1.0E+02 1.0E+01 R² = 0.901 1.0E+01 R² = 0.938 1.0E+00 1.0E+00 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 1.0E+09 1.0E+09 EICAR MPA 1.0E+08 1.0E+08 1.0E+07 1.0E+07 1.0E+06 1.0E+06 1.0E+05 1.0E+05 1.0E+04 1.0E+04 1.0E+03 1.0E+03 1.0E+02 1.0E+02 R² = 0.880 R² = 0.889 1.0E+01 1.0E+01 1.0E+00 1.0E+00 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 Design of small molecule inhibitors of RNA virus replication No increased mutation frequency in pre-extinction population Ribavirin EICAR MPA 1.0E+09 1.0E+09 1.0E+09 1.0E+08 1.0E+08 1.0E+08 1.0E+07 1.0E+07 1.0E+07 1.0E+06 1.0E+06 1.0E+06 1.0E+05 1.0E+05 1.0E+05 1.0E+04 1.0E+04 1.0E+04 1.0E+03 1.0E+03 1.0E+03 1.0E+02 1.0E+02 1.0E+02 1.0E+01 1.0E+01 1.0E+01 1.0E+00 1.0E+00 1.0E+00 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 VC 300 240 180 120 60 12 [ µg/ml] VC 12.5 2.5 0.5 0.1 [µg/ml] VC 1.25 0.25 0.05 0.01 [µg/ml] Unique mutations/1000 NT Reference Virus control Ribavirin EICAR MPA 1.22 1.74 1.49 1.40 1.32 Leyssen et al., (2006) Mol. Pharm Design of small molecule inhibitors of RNA virus replication Design of small molecule inhibitors of RNA virus replication Merimepodib Mycophenolic acid (CellCept) Design of small molecule inhibitors of RNA virus replication Flaviridae Genus Hepacivirus Genus Flavivirus hepatitis C virus Genus Pestivirus e.g. bovine viral diarrhea virus (surrogate) Design of small molecule inhibitors of RNA virus replication Evaluation of the anti-BVDV activity of novel classes of compounds Collaboration with ~20 medicinal chemists world-wide Identification of a selective inhibitor of BVDV replication Analogue with F increased activity: N EC = 1.5 µM N 50 N F F F F N N þ N F F F ý N F Analogue with F N N Hit with decreased activity: F EC50 = 16 µM EC50 >100 µM F Purstinger et al., Bioorg. Med. Chem. Letters. (2006) Design of small molecule inhibitors of RNA virus replication Building a structure-activity relationship : Hit to lead N N N þ ý Br Purstinger et al., Bioorg. Med. Chem. Letters. (2006) Design of small molecule inhibitors of RNA virus replication Study of the mechanism of action Paeshuyse et al., J. Virol. Generation and characterisation of resistant virus (2006) Study of the molecular mechanism of action A B BPIP Phe224 Ala 221 Ala 222 C F224S mutation in polymerase is responsible for resistance Design of small molecule inhibitors of RNA virus replication Study of the mechanism of action of other BVDV inhibitors AG110 is cross-resistant with BPIP E291G mutation only 7Å away from BPIP-induced mutation Paeshuyse et Identification of a hot spot for inhibition of viral replication al., J.
Load more

Recommended publications
  • COVID-19 Drugs: Are There Any That Work? 24 August 2020, by from Mayo Clinic News Network, Mayo Clinic News Network
    COVID-19 drugs: Are there any that work? 24 August 2020, by From Mayo Clinic News Network, Mayo Clinic News Network dysfunction and lung injury from inflammation. A recent study found it reduced deaths by about 30% for people on ventilators and by about 20% for people who needed supplemental oxygen. The U.S. National Institutes of Health has recommended this drug for people hospitalized with COVID-19 who are on mechanical ventilators or need supplemental oxygen. Other corticosteroids, such as prednisone, methylprednisolone or hydrocortisone, may be used if dexamethasone isn't available. However, their effectiveness isn't yet known. Dexamethasone and other corticosteroids may be harmful if given for less severe COVID-19 infection. Credit: Unsplash/CC0 Public Domain Anti-inflammatory therapy. Researchers study many anti-inflammatory drugs to treat or prevent dysfunction of several organs and lung injury from infection-associated inflammation. Question: I've heard several drugs mentioned as possible treatments for COVID-19. What are they Immune-based therapy. Researchers are studying and how do they work? the use of a type of immune-based therapy called convalescent plasma. Convalescent plasma is Answer: Although there is no product approved by blood donated by people who've recovered from the Food and Drug Administration to treat COVID-19. It is used to treat people who are coronavirus disease 2019 (COVID-19), many seriously ill with the disease. medications are being tested. Drugs being studied that have uncertain One investigational drug called remdesivir has effectiveness. Researchers are studying been authorized by the FDA for emergency use amlodipine, ivermectin, losartan and famotidine.
    [Show full text]
  • COVID-19: Predicting Inhibition of the Main Protease and Therapeutic Intracellular Accumulation and Plasma and Lung Concentratio
    COVID-19: predicting inhibition of the main protease and therapeutic intracellular accumulation and plasma and lung concentrations of repurposed inhibitors Clifford Fong To cite this version: Clifford Fong. COVID-19: predicting inhibition of the main protease and therapeutic intracellu- lar accumulation and plasma and lung concentrations of repurposed inhibitors. [Research Report] Eigenenergy. 2020. hal-02917312 HAL Id: hal-02917312 https://hal.archives-ouvertes.fr/hal-02917312 Submitted on 20 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. COVID-19: predicting inhibition of the main protease and therapeutic intracellular accumulation and plasma and lung concentrations of repurposed inhibitors Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: COVID-2019 or SARS-CoV-2; SARS-CoV; MERS; 3C-like protease, or 3CLpro, pro or M ; inhibition; IC50, EC50, EC90, host cell membrane transport, AUC, Cmax, linear free energy relationships, HOMO-LUMO; quantum mechanics; Abbreviations: Structure
    [Show full text]
  • Antivirals Against the Chikungunya Virus
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 June 2021 Review Antivirals against the Chikungunya Virus Verena Battisti 1, Ernst Urban 2 and Thierry Langer 3,* 1 University of Vienna, Department of Pharmaceutical Sciences, Pharmaceutical Chemistry Division, A-1090 Vienna, Austria; [email protected] 2 University of Vienna, Department of Pharmaceutical Sciences, Pharmaceutical Chemistry Division, A-1090 Vienna, Austria; [email protected] 3 University of Vienna, Department of Pharmaceutical Sciences, Pharmaceutical Chemistry Division, A-1090 Vienna, Austria; * Correspondence: [email protected] Abstract: Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has re-emerged in recent decades, causing large-scale epidemics in many parts of the world. CHIKV infection leads to a febrile disease known as chikungunya fever (CHIKF), which is characterised by severe joint pain and myalgia. As many patients develop a painful chronic stage and neither antiviral drugs nor vac- cines are available, the development of a potent CHIKV inhibiting drug is crucial for CHIKF treat- ment. A comprehensive summary of current antiviral research and development of small-molecule inhibitor against CHIKV is presented in this review. We highlight different approaches used for the identification of such compounds and further discuss the identification and application of promis- ing viral and host targets. Keywords: Chikungunya virus ; alphavirus; antiviral therapy; direct-acting antivirals; host-directed antivirals; in silico screening; in vivo validation, antiviral drug development 1. Introduction Chikungunya virus (CHIKV) is a mosquito-borne alphavirus and belongs to the Togaviridae family. The virus was first isolated from a febrile patient in 1952/53 in the Makonde plateau (Tanzania) and has been named after the Makonde word for “that which bends you up”, describing the characteristic posture of patients suffering severe joint pains due to the CHIKV infection [1].
    [Show full text]
  • What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV And
    What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials by Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed edited by Mark Harrington & Bob Huff Treatment Action Group New York, NY, USA July 2005 e thymidine • BI-201 • Racivir (PSI 5004) • TMC-278 • Diarylpyrimidine (DAPY) • 640385 • Reverset (D-D4FC) • JTK-303 • UK-427 (maraviroc) • Amdoxovir • AMD-070 • Vicriviroc LIPO-5 • GTU-Multi-HIV • pHIS-HIV-B • rFPV-HIV-B • ADMVA • GSK Protein HIV Vaccine TBC-M335 (MVA) • TBC-F357 (FPV) • TBC-F349 (FPV) • LIPO-4T (LPHIV-1) • LFn-p24 • H G • Oligomeric gp140/MF59 • VRC-HIVDNA-009-00-VP • PolyEnv1 • ISS P-001 • EP HIV- • BufferGel • Lactin-V • Protected Lactobacilli in combination with BZK • Tenofovir/PMPA G ulose acetate/CAP) • Lime Juice • TMC120 • UC-781 • VivaGel (SPL7013 gel) • ALVAC Ad5 • Autologous dendritic cells pulsed w/ALVAC • Autologous dendritic cell HIV vaccination x • Tat vaccine • GTU-nef DNA vaccine • Interleukin-2 (IL-2) • HE2000 • Pegasys (peginter L-4/IL-13 trap • Serostim • Tucaresol • MDX-010 anti-CTLA4 antibody • Cyclosporine A • 496 • HGTV43 • M87o • Vertex • VX-950 • Idenix • Valopicitabine (NM283) • JTK-003 mplant • Albuferon • Celgosivir (MBI-3253) • IC41 • INN0101 • Tarvicin • ANA971 (oral) floxacin, Tequin • J, TMC207 (ex R207910) • LL-3858 • M, moxifloxacin, Avelox • PA-824 Acknowledgements. Thanks to our intrepid editors, Bob Huff, copy-editor Andrea Dailey, and proof-reader Jen Curry, to awesome layout expert Lei Chou, to webmaster Joel Beard, to Joe McConnell for handling administrative matters related to the report, and most of all to the board and supporters of TAG for making our work possible.
    [Show full text]
  • Differences in Clinical Outcomes Among Hepatitis C Genotype 1
    Clinical and Experimental Gastroenterology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis Eric Druyts1 Background: With the development of new direct acting antiviral (DAA) therapy for hepatitis Edward J Mills1,2 C, the backbone peginterferon alpha used may be of importance in maximizing treatment Jean Nachega3 outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment Christopher O’Regan4 discontinuation among hepatitis C genotype 1-infected patients given peginterferon alpha-2a Curtis L Cooper5 plus ribavirin or peginterferon alpha-2b plus ribavirin were determined using a meta-analysis. Methods: Randomized trials examining peginterferon alpha-2a or peginterferon alpha-2b co- 1Faculty of Health Sciences, University administered with ribavirin for 48 weeks were included. Data were extracted on SVR, relapse, of Ottawa, Ottawa, ON, Canada; For personal use only. 2Department of Clinical Epidemiology and treatment discontinuations for treatment-naïve and treatment-experienced patients. Pooled and Biostatistics, McMaster University, proportions using fixed and random effects meta-analysis were calculated. Hamilton, ON, Canada; 3Centre for Infectious Diseases, Stellenbosch Results: Twenty-six trials provided data on patients treated with peginterferon alpha-2a plus University, Stellenbosch,
    [Show full text]
  • Existing Drugs Considered As Promising in COVID-19 Therapy
    International Journal of Molecular Sciences Review Existing Drugs Considered as Promising in COVID-19 Therapy Edyta Janik 1 , Marcin Niemcewicz 1 , Marcin Podogrocki 1, Joanna Saluk-Bijak 2 and Michal Bijak 1,* 1 Biohazard Prevention Centre, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] (E.J.); [email protected] (M.N.); [email protected] (M.P.) 2 Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel./Fax: +48-42-635-43-36 Abstract: COVID-19 is a respiratory disease caused by newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease at first was identified in the city of Wuhan, China in December 2019. Being a human infectious disease, it causes high fever, cough, breathing problems. In some cases it can be fatal, especially in people with comorbidities like heart or kidney problems and diabetes. The current COVID-19 treatment is based on symptomatic therapy, so finding an appropriate drug against COVID-19 remains an immediate and crucial target for the global scientific community. Two main processes are thought to be responsible for the COVID-19 pathogenesis. In the early stages of infection, disease is determined mainly by virus replication. In the later stages of infection, by an excessive immune/inflammatory response, leading to tissue damage. Therefore, the main treatment options are antiviral and immunomodulatory/anti-inflammatory agents.
    [Show full text]
  • Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: a Century-Long Story
    Review Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story Rand Naffouje 1, Punita Grover 1, Hongyang Yu 2,3, Arun Sendilnathan 1, Kara Wolfe 1,4, Nazanin Majd 5, Eric P. Smith 6, Koh Takeuchi 7, Toshiya Senda 2,3, Satoshi Kofuji 8 and Atsuo T. Sasaki 1,4,9,10,* 1 Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (P.G.); [email protected] (A.S.); [email protected] (K.W.); [email protected] (A.T.S.) 2 Structural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tokyo 135-0063, Japan; [email protected] (H.Y.); [email protected] (T.S.) 3 Department of Accelerator Science, School of High Energy Accelerator Science, SOKENDAI (the Graduate University for Advanced Studies), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan 4 Department of Cancer Biology, University of Cincinnati College of Medicine, OH 45267, USA 5 Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; [email protected] 6 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] 7 Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Science and Technology, 2-3-26 Aomi, Koto, Tokyo 135-0063, Japan; [email protected] 8 Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan; [email protected] 9 Department of Neurosurgery, Brain Tumor Center at UC Gardner Neuroscience Institute, Cincinnati, OH 45267, USA 10 Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan * Correspondence: [email protected] Received: 9 August 2019; Accepted: 2 September 2019; Published: 11 September 2019 Abstract: The purine nucleotides ATP and GTP are essential precursors to DNA and RNA synthesis and fundamental for energy metabolism.
    [Show full text]
  • 24 March 2011 (24.03.2011) W O 201 1 /03 523 1 a 1
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date 24 March 2011 (24.03.2011) W O 201 1 /03 523 1 A 1 (51) International Patent Classification: (74) Agents: WARD, John et al.; Gilead Sciences, Inc., 333 C07D 487/04 (2006.01) Lakeside Drive, Foster City, CA 94404 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 10/049471 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 20 September 2010 (20.09.2010) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Langi English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 61/244,297 2 1 September 2009 (21 .09.2009) US SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): GILEAD SCIENCES, INC. [US/US]; 333 Lakeside (84) Designated States (unless otherwise indicated, for every Drive, Foster City, CA 94404 (US).
    [Show full text]
  • Honey As an Antiviral Agent Against Respiratory Syncytial Virus
    http://researchcommons.waikato.ac.nz/ Research Commons at the University of Waikato Copyright Statement: The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand). The thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use: Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person. Authors control the copyright of their thesis. You will recognise the author’s right to be identified as the author of the thesis, and due acknowledgement will be made to the author where appropriate. You will obtain the author’s permission before publishing any material from the thesis. Honey as an antiviral agent against respiratory syncytial virus A thesis submitted in partial fulfilment of the requirements for the Degree of Master of Science in Biological Sciences at The University of Waikato by Parvaneh Palma Zareie 2011 i Abstract Respiratory syncytial virus is the most frequent cause of hospitalization for viral respiratory infections in infants and young children worldwide. It also severely affects immunocompromised adults and the elderly, however, despite decades of efforts, there is no proven effective treatment for RSV infection and attempts at vaccine development have been hampered by several major obstacles. A large amount of research has established the potent antibacterial activity of honey, but its activity against viral species has been the subject of only a small number of studies. These were with viruses which cause localised infections in which honey could be used topically.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • Gemcitabine, a Broad-Spectrum Antiviral Drug, Suppresses
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 70), pp: 115315-115325 Research Paper Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion Kyungjin Lee1,*, Dong-Eun Kim3,*, Kyoung-Soon Jang5, Seong-Jun Kim1, Sungchan Cho3,4 and Chonsaeng Kim1,2 1Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, South Korea 2Department of Medicinal and Pharmaceutical Chemistry, Korea University of Science and Technology, Daejeon, South Korea 3Anticancer Agent Research Center, Korea Research Institute of Bioscience & Biotechnology, Cheongju, South Korea 4Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, South Korea 5Biomedical Omics Group, Korea Basic Science Institute, Cheongju, South Korea *These authors have contributed equally to this work Correspondence to: Sungchan Cho, email: [email protected] Chonsaeng Kim, email: [email protected] Keywords: enterovirus; gemcitabine; antiviral drug; pyrimidine biosynthesis; interferon-stimulated genes (ISGs) Received: June 13, 2017 Accepted: December 05, 2017 Published: December 15, 2017 Copyright: Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Gemcitabine, an anti-cancer chemotherapy drug, has additionally shown the antiviral activity against a broad range of viruses and we also have previously reported its synergistic antiviral activity with ribavirin against enteroviruses. As a cytidine analog, gemcitabine has been reported to have an inhibitory activity on the pyrimidine biosynthesis.
    [Show full text]
  • Emerging Drugs for Respiratory Syncytial Virus Infection Europe
    Europe PMC Funders Group Author Manuscript Expert Opin Emerg Drugs. Author manuscript; available in PMC 2009 July 06. Published in final edited form as: Expert Opin Emerg Drugs. 2009 June ; 14(2): 207–217. doi:10.1517/14728210902946399. Europe PMC Funders Author Manuscripts Emerging drugs for respiratory syncytial virus infection Wieslawa Olszewska and Peter Openshaw† National Heart and Lung Institute, Centre for Respiratory Infection, Imperial College London, St Mary's Campus, Norfolk Place, Paddington, W2 1PG, London, UK Abstract Although respiratory syncytial virus (RSV) was discovered > 40 years ago, treatment remains largely supportive. There are no safe and effective vaccines or specific treatments other than prophylaxis with passive antibody therapy (palivizumab). However, there are good reasons to think that the scene may soon change. As the pace of development of anti-viral drugs accelerates and optimism over vaccines increases, novel therapies are set to make a major impact in the management of this very common infection. The use and effect of such interventions are not easy to anticipate, but could ultimately include the interruption of RSV's transmission resulting in profound changes to the impact of RSV on human health. Keywords antisense RNA; anti-viral drugs; fusion inhibitors; RSV; therapeutic antibodies 1. Background Europe PMC Funders Author Manuscripts Respiratory syncytial virus (RSV) is a common cold agent and the chief worldwide viral cause of moderate-to-severe acute upper and lower respiratory tract illness in infancy. Almost all children are infected by 3 years of age [1,2], most suffering only mild symptoms with rhinorrhea, cough, fever and sometimes wheeze generally resolving in < 2 weeks.
    [Show full text]